Sign In
Buy BAX
$18.54
-0.140 (-0.749%)
At Close: Jun 03, 2026
Medical device maker Baxter beats sales and profit estimates on strong demand
08:32am, Thursday, 08'th Feb 2024
Baxter International beat Wall Street expectations for fourth-quarter sales and profit on Thursday on strong demand for its medical devices and improvements in the supply chain environment.
MoneyShow's Best Investment Ideas For 2024: Part 2
05:30pm, Friday, 26'th Jan 2024
MoneyShow presents top investment ideas for 2024 from their contributors. This year's edition presents a broad mix of conservative income stocks, more speculative but potentially more rewarding growth
Baxter to Host Fourth-Quarter 2023 Financial Results Conference Call for Investors
04:15pm, Thursday, 04'th Jan 2024
DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a global medtech leader, will host a conference call to discuss its fourth-quarter 2023 financial results on Thursday, February
Reasons to Retain Baxter International (BAX) in Your Portfolio
09:01am, Thursday, 14'th Dec 2023
Baxter International's (BAX) robust growth across all geographies, along with transformational initiatives, boosts confidence. However, pandemic-related disruption continues to hurt sales.
Baxter to Present at 42nd Annual J.P. Morgan Healthcare Conference
04:30pm, Wednesday, 13'th Dec 2023
DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a global medtech leader, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2024. José (Jo
Strategist: Buy Baxter stock, skip Eli Lilly stock
04:18pm, Tuesday, 12'th Dec 2023
Novo Nordisk (NVO) was named Yahoo Finance's Company of the Year thanks to the success of its diabetes and weight loss drugs, Ozempic and Wegovy. But there are other ways you can play the GLP-1 hype.
Baxter International: A Cheap Big Pharma Stock With Improving Earnings And +3% Dividend Yield
02:29am, Tuesday, 12'th Dec 2023
Baxter International stock rated Buy, agreeing with Wall Street consensus. Tailwinds coming from positive revenue, earnings, and equity growth. Cheap share price below moving average combined with +3%
Baxter (BAX) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates
12:00am, Friday, 03'rd Nov 2023
The headline numbers for Baxter (BAX) give insight into how the company performed in the quarter ended September 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estima
Baxter International beats Q3 profit estimates on strong demand for medical devices
09:08am, Thursday, 02'nd Nov 2023
Baxter International on Thursday beat Wall Street expectations for third-quarter revenue and profit, as a recovery in surgical procedure volumes after the pandemic helped drive the demand for its medi
BAX vs. SYK: Which Stock Is the Better Value Option?
12:47pm, Monday, 30'th Oct 2023
Investors looking for stocks in the Medical - Products sector might want to consider either Baxter International (BAX) or Stryker (SYK). But which of these two stocks is more attractive to value inves
Baxter (BAX) to Report Q3 Earnings: Is a Beat in Store?
09:46am, Monday, 30'th Oct 2023
Baxter's (BAX) third-quarter results are likely to reflect growth in elective surgical procedures, offset by currency movement. Hillrom's products might have boosted sales.
The Value Deepens for Medtech Stocks: Reversal Imminent
10:21am, Monday, 23'rd Oct 2023
Results from Johnson & Johnson NYSE: JNJ and Abbott Laboratories NYSE: ABT foreshadow good news for MedTech investors. Both companies outperformed on the top and bottom lines, driven by broad strength
Baxter's (BAX) New Launch to Enable Earlier Treatment of Eye
12:02pm, Wednesday, 18'th Oct 2023
Baxter's (BAX) latest offering is likely to enable a more digitally-connected primary care examination and support faster diagnosis for earlier treatment of eye conditions.
What other industries could weight loss drugs disrupt?
07:10pm, Wednesday, 11'th Oct 2023
Jared Holz, Mizuho health care sector strategist, joins the ‘Fast Money' traders to discuss Novo Nordisj's kidney trial outcomes and the impact of weight loss drugs on the health care sector.
Why Investors Punished Baxter International Stock Today
06:49pm, Wednesday, 11'th Oct 2023
A drug made by a rival tested well in a clinical trial for kidney disease. That treatment is currently a very hot product, but for different indications.
